Sign In
Buy KYKOF
$14.20
+0 (+0%)
At Close: Jul 10, 2026
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
08:30am, Tuesday, 23'rd Jun 2026
New online resource brings together practical information, community perspectives, and expert guidance tailored to people with XLH across ages and life stages New online resource brings together pract
New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation New Clinical Data, Patient Reported O
Kyowa Kirin stops development of skin condition treatment
08:47am, Tuesday, 03'rd Mar 2026
Kyowa Kirin on Tuesday said it is discontinuing all ongoing trials of its experimental drug to treat skin conditions.
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
01:09pm, Friday, 30'th Jan 2026
Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ: AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration.
Kyowa Kirin (OTCMKTS:KYKOF) Trading Down 4.5% – Time to Sell?
01:52am, Wednesday, 17'th Dec 2025
Kyowa Kirin Co., Ltd. (OTCMKTS:KYKOF - Get Free Report) shares were down 4.5% during mid-day trading on Tuesday. The stock traded as low as $15.8450 and last traded at $15.8450. Approximately 1,957 sh
TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors' decision to appoint Abdul Mullick,
Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential for
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region
03:00am, Monday, 03'rd Nov 2025
GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty P
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
02:40am, Thursday, 30'th Oct 2025
The licensed small molecule program aims to address significant unmet needs for autoimmune diseases . Program adds to Boehringer's pipeline and its commitment to deliver breakthrough therapies for p
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
09:01am, Tuesday, 19'th Aug 2025
First-of-its kind tool to guide HCPs on what to consider when staging patients with Mycosis Fungoides and Sézary Syndrome First-of-its kind tool to guide HCPs on what to consider when staging patient
Kyowa Kirin Co., Ltd. (KYKOF) Q2 2025 Earnings Call Transcript
09:08pm, Friday, 01'st Aug 2025
Kyowa Kirin Co., Ltd. (OTCPK:KYKOF) Q2 2025 Earnings Conference Call July 31, 2025 9:00 PM ET Company Participants Abdul Mullick - Representative Director, President & Chief Operating Officer Masashi
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
08:00am, Tuesday, 29'th Jul 2025
PRINCETON, N.J. and TOKYO , July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
-Agreement extends one of the world's most enduring alliances for drug discovery- -Landmark discoveries from partnership have led to novel drug candidates, including an immunotherapy for moderate to
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025
08:00am, Wednesday, 26'th Feb 2025
PRINCETON, N.J. , Feb. 26, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
GALASHIELS & MARLOW, England & BAAR, Switzerland--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd., and Swixx BioPharma AG today announced that the C
